In recent years, the incidence of cutaneous melanoma has increased more than that of any other cancer. Dacarbazine is considered the gold standard for treatment, having a response rate of 15% to 20%, ...

Please provide your email address to receive an email when new articles are posted on . Prior research showed nivolumab (Opdivo, Bristol-Myers Squibb) — a PD-1 immune checkpoint inhibitor — was ...

CHICAGO—Ipilimumab in combination with dacarbazine significantly improved overall survival (OS) in metastatic melanoma compared with dacarabazine alone, according to data presented at the American ...

Janssen Research & Development, LLC (Janssen) announced data from the Phase 3 multicenter study SAR3007, which demonstrated a significant improvement in progression-free survival (PFS) with ...

Chinese patients with advanced acral melanoma achieved a small but significant increase in progression-free survival when treated with toripalimab versus dacarbazine. While the overall response rate ...

September 16, 2008 (Stockholm, Sweden) — One of the largest trials conducted in advanced melanoma to date has found that the oral drug temozolomide (Temodal, Schering-Plough) was no better than ...

Poly adenosine diphosphate (ADP)-ribose polymerase (PARP) is essential in cellular processing of DNA damage via the base excision repair pathway (BER). The PARP inhibition can be directly cytotoxic to ...

Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227 Clinical trials frequently include ...

Lenvatinib Meets Primary Endpoint in Phase 3 SELECT Trial Eisai announced results from a Phase 3 trial investigating the use of eribulin vs. dacarbazine in patients with advanced soft tissue sarcomas.

PFS significantly higher with nivolumab, doxorubicin, vinblastine, and dacarbazine versus brentuximab vedotin-AVD.

The safety of oral sorafenib up to a maximum protocol-specified dose combined with dacarbazine in patients with metastatic, histologically confirmed melanoma was investigated in a phase I ...

In recent years, the incidence of cutaneous melanoma has increased more than that of any other cancer. Dacarbazine is considered the gold standard for treatment, having a response rate of 15% to 20%, ...